This is a working overview of anti-doping, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-23. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
A collection of reprints of notable reviews from the magazine's history, along with retrospective commentary on each game. In addition to reviews of popular titles (including the three "ten out of ten" scores that had been awarded during that period), it also included Edge's comments on notable hyped disappointments such as Rise of the Robots and Daikatana. The issue also included an index of the content of those 100 issues of the magazine. "Retro: The guide to classic videogame playing and collecting" (2002)
=== Mechanism of action === Dasiglucagon operates through the same mechanism as endogenous glucagon, acting as an agonist at glucagon receptors expressed throughout the body, which are G-coupled receptors. Binding to liver glucagon receptors, dasiglucagon activates Gsα and Gq, resulting in the activation of adenylate cyclase. This, in turn, increases intracellular cyclic AMP levels, stimulating glycogenolysis and gluconeogenesis in the liver. As glucose is primarily released from liver glycogen stores, the presence of glycogen stores in the liver is essential for dasiglucagon to exert its antihypoglycemic effects
===== Serpentes (Snakes) ===== Clade Scolecophidia (Blindsnakes) Family Typhlopidae Anilios bituberculatus, Prong-snouted blind snake (2021) Indotyphlops braminus, Brahminy blindsnake, (2022) Clade Booidea Family Pythonidae Morelia viridis, Green Tree Python (2022) Python bivittatus, Burmese python (2013) Python regius, Ball python (2020) Simalia boeleni, Boelen's Python (2022) Family Boidae Boa constrictor, Boa constrictor (2019) Charina bottae, Rubber boa, (2022) Clade Caenophidia Family Viperidae Azemiops feae, Fea's viper (2022) Bothrops jararaca, Jararaca lancehead, (2021) Crotalus adamanteus, Eastern diamondback rattlesnake (2021) Crotalus mitchellii pyrrhus, southwestern speckled rattlesnake (2014) Crotalus oreganus helleri, southern Pacific rattlesnake (2023) Crotalus tigris, Tiger rattlesnake (2021) Crotalus viridis, Great Plains rattlesnake (2018) Daboia siamensis, Eastern Russell's viper (2022) Deinagkistrodon acutus, Five-pacer viper (2016) Protobothrops flavoviridis, Okinawa Habu (2018) Protobothrops mucrosquamatus, Taiwanese Habu (2017, 2024) Trimeresurus albolabris, White-lipped tree pit viper (2024) Cerastes gasperetti, Arabian horned viper (2025) Family Homalopsidae Myanophis thanlyinesis, (No common name), (2021) Family Colubridae Ahaetulla prasina, Asian vine snake (2023) Arizona elegans occidentalis, California glossy snake (2022) Chrysopelea ornata, Ornate Flying Snake (2023) Diadophis punctatus, ring-necked snake (2023) Dolichophis caspius, Caspian whipsnake (2020) Elaphe carinata, King ratsnake (2024) Pantherophis guttatus, corn snake (2014) Pantherophis obsoletus, Leucistic Texas Rat Snake (2021) Ptyas mucosa, Oriental rat snake (2024) Thamnophis sirtalis, Common garter snake (2018) Thermophis baileyi, Tibetan hot-spring snake (2018) Family Elapidae Bungarus multicinctus, Many-banded krait (2022) Emydocephalus ijimae, Ijima's turtle-headed sea snake, (2019) Hydrophis curtus, Shaw's Sea Snake (2020) Hydrophis cyanocinctus, blue-banded sea snakes (2021) Hydrophis melanocephalus, slender-necked sea snake, (2019) Laticauda colubrina, yellow-lipped sea krait, (2019) Laticauda laticaudata, blue-lipped sea krait, (2019) Naja atra, Chinese cobra (2024) Naja naja, Indian cobra (2020) Notechis scutatus, mainland tiger snake (2022) Ophiophagus hannah, king cobra (2013) Pseudonaja textilis, eastern brown snake (2022)
==== Limitations ==== Because relatively few cells are counted in the manual differential, the variability is higher than in automated techniques, especially when cells are present in low amounts. For example, in a sample containing 5 percent monocytes, the manual differential results could be between 1 and 10 percent due to sampling variation. Additionally, cell identification is subjective and the accuracy depends on the skills of the person reading the slide. Poor blood smear preparation can cause an uneven distribution of white blood cells, resulting in inaccurate counting, and improper staining can impede cell identification. Overall, manual differential counts exhibit coefficients of variation (CVs) ranging from 5 to 10 percent, while automated differential counts of normal neutrophils and lymphocytes have CVs of about 3 percent. In leukemias and other hematologic malignancies, the lineage and genetic characteristics of white blood cells have important implications for treatment and prognosis, and the microscopic appearance of the cells is often insufficient for accurate classification. In these cases, other techniques such as immunophenotyping by flow cytometry or special staining can be used to definitively identify the cells.
Sources: en.wikipedia.org
== History == 2,3-Dihydro-LSD was first described in the scientific literature by Charles Gorodetzky and Harris Isbell at the Addiction Research Center of the National Institute of Mental Health (subsequently part of the National Institute on Drug Abuse) by 1964. However, it had first been synthesized and studied in animals by Botand Berde and Rudolph Bircher at Sandoz Pharmaceuticals, but their findings were unpublished. Sandoz Pharmaceuticals supplied the 2,3-dihydro-LSD used by Gorodetzky and Isbell in their clinical study.
=== Cholesterol control === There is inconsistent evidence regarding the effect of LDL-cholesterol levels on stroke risk after TIA. Elevated cholesterol may increase ischemic stroke risk while decreasing the risk of hemorrhagic stroke. While its role in stroke prevention is unclear, statin therapy has been shown to reduce all-cause mortality and may be recommended after TIA.
Succinate-Q oxidoreductase, also known as complex II or succinate dehydrogenase, is a second entry point to the electron transport chain. It is unusual because it is the only enzyme that is part of both the citric acid cycle and the electron transport chain. Complex II consists of four protein subunits and contains a bound flavin adenine dinucleotide (FAD) cofactor, iron–sulfur clusters, and a heme group that does not participate in electron transfer to coenzyme Q, but is believed to be important in decreasing production of reactive oxygen species. It oxidizes succinate to fumarate and reduces ubiquinone. As this reaction releases less energy than the oxidation of NADH, complex II does not transport protons across the membrane and does not contribute to the proton gradient.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.